PremiumRatingsPromising Clinical Trial Results and Strategic Pipeline Development Position Argenx Se as a Strong Investment Prospect Argenx SE Reports Promising Phase 2 Results for Efgartigimod in Autoimmune Diseases Argenx presents new Efgartigimod data at EULAR 2025 PremiumCompany AnnouncementsArgenx SE Announces AGM Results and Key Resolutions Argenx added to Best Ideas List at Wedbush Argenx pullback brings ‘attractive buying opportunity,’ says Citi PremiumThe FlyArgenx price target lowered to EUR 525 from EUR 575 at Deutsche Bank Argenx Reports Record Growth and Strategic Success Argenx price target lowered to EUR 700 from EUR 740 at JPMorgan 
